Texas Continues to Target Pharma Patient Support Programs Under the Texas Anti-Kickback Statute

Key Takeaways The Texas Attorney General secured a $45 million settlement with Gilead Sciences, just four months after a $34 million AstraZeneca settlement. Both resolved allegations that manufacturer patient support programs functioned as illegal inducements to Texas prescribers. Texas treats free nursing services and patient education as in-kind remuneration under the Texas Anti-Kickback Statute and … Continued